Skip to main content
NCBI home page
Case Reports in Immunology logoLink to Case Reports in Immunology
. 2021 May 25;2021:5574944. doi: 10.1155/2021/5574944

Collagenous Gastritis in Primary Selective IgM Deficiency: Transition to EBV+ Gastric Adenocarcinoma

Tejal Narsai 1, Houfen Su 1, David Braxton 2, Sudhir Gupta 1,✉
PMCID: PMC8172285  PMID: 34123443

Abstract

Selective IgM deficiency (SIgMD) and isolated collagenous gastritis are two independent rare disorders. Our purpose is to report the 1st case of SIgMD and isolated collagenous gastritis and collagenous gastritis that has transitioned to EBV + gastric adenocarcinoma. Gastric biopsy tissue was analyzed by EBV-related encoded RNA in situ hybridization assay. Subsets of CD4, CD8, T follicular helper cells (TFH), and members of the “regulatory lymphocytes club” were measured with multiple panels of monoclonal antibodies and isotype controls by multicolor flow cytometry. The patient was diagnosed with SIgMD (extremely low serum IgM 9 mg/dl and normal IgG and IgA and exclusion of secondary causes of low IgM). Soon after SIgMD diagnosis, the patient developed collagenous gastritis and, 8 years later, developed gastric adenocarcinoma that was positive for EBV. An extensive immunological analysis revealed reduced naïve CD4 and CD8 effector memory T cells and increased naïve and central memory CD8 T cells. Among the circulating follicular helper T cells (cTFH), TFH1 and TFH2 were increased whereas TFH17 was decreased. CD4 Treg cells and TFR cells were increased, whereas Breg and CD8 Treg were comparable to control. In conclusion, SIgMD may be associated with isolated collagenous gastritis, and collagenous gastritis may transition to EBV + gastric adenocarcinoma. A role of regulatory lymphocytes in gastric cancer is discussed.

1. Introduction

SIgMD was first described in 1967 [1]; however, only recently has it been incorporated as a primary immunodeficiency in IUIS classification [2]. SIgMD is characterized by a serum IgM below 2 SD below the mean with normal serum IgG and IgA, and exclusion of secondary causes of low serum IgM [3]. Patients with SIgMD may be asymptomatic or present with recurrent infections and allergic and/or autoimmune manifestations [4, 5]. A number of malignant disorders have been reported in patients with SIgMD [6, 7]; however, it is unclear whether there is a true increase in the prevalence of malignancy in SIgMD.

Collagenous gastroenteritis includes collagenous gastritis, collagenous sprue, and collagenous colitis and is characterized by subepithelial collagen deposition and infiltration by inflammatory mononuclear cells in the lamina propria [8–12]. Among collagenous gastroenteritides, collagenous gastritis is very rare and isolated collagenous gastritis is predominantly present in children. In adults, it is generally associated with diffused disease including collagenous colitis [13]. Kamimura et al. reviewed data on all 60 known cases of collagenous gastritis reported until 2015, and no progression of collagenous gastritis to gastric carcinoma was observed [14].

Collagenous gastritis has not been reported as a predisposing factor for gastric cancer, and collagenous gastritis has not been reported in SIgMD. Furthermore, progression of collagenous gastritis to gastric adenocarcinoma has never been reported.

We present, to the best of our knowledge, the first case of SIgMD with isolated collagenous gastritis and transition of collagenous gastritis to gastric adenocarcinoma.

2. Materials and Methods

2.1. Case Description

In 2017, a 53-year-old male was referred to us with a history of asthma and allergic rhinitis and history of recurrent upper respiratory tract infections. During his teenage years, he reported having frequent episodes of acute sinusitis. In his 30 s, he was diagnosed with an episode of meningitis, as well as multiple pneumonias. No further details were available regarding nature of infections. No prior immunological workup was performed. His asthma was well controlled on inhaled corticosteroid therapy. His allergic rhinitis was well controlled with allergen immunotherapy and nasal fluticasone spray. An immunologic evaluation was performed. the patient had severely reduced IgM (9 mg/dl; control 37–336) with normal IgG (698 mg/dl; control 660–1,660 mg/dl) and IgA (145 mg/dl; control 80–400 mg/dl) and normal response to pneumococcal polysaccharide, diphtheria, and tetanus toxoid. CD3+, CD4+, CD8+, CD19+ B cells, and CD3-CD16+CD56+ NK cells were normal; secondary causes of low IgM were excluded. Therefore, a diagnosis of primary SIgMD was established. Since 2017, immunoglobulin levels were frequently repeated on several occasions. Total IgG ranged between 698 mg/dl–718 mg/dl, and total IgM ranged between <9 mg/dl and 17 mg/dl. Soon after, he was evaluated for epigastric burning and severe upper abdominal pain. An endoscopy was performed, and biopsies showed collagenous gastritis (Figure 1). He was started on twice daily proton pump inhibitor and H2 blocker therapy, with relief of his symptoms. His gastritis was monitored with annual endoscopies with random biopsies. Eight years later (2020), his screening endoscopy showed a new polyp that, on biopsy, revealed poorly differentiated gastric adenocarcinoma that was positive for EBV (Figure 2). Serum EBV-VCA IgM antibodies (U/ml)- undetected, EBV-VCA IgG antibodies (U/ml)-388 (control <22), EBNA-IgG antibodies (U/ml)- 55.2 (control <22), EBV-EA diffuse antibodies (U/ml)-<5 (control <11), and EBV-PCR-negative were found. He had no new symptoms. A PET CT was negative for metastatic lesion. He underwent total gastrectomy and had 0/22 positive lymph nodes. No chemotherapy was instituted. He is doing well clinically.

Figure 1.

Figure 1

Open in a new tab

(a) 4x magnification of the results of upper endoscopy biopsy showing nonspecific chronic inflammatory infiltrate with a thickened subepithelial collagen table. (b) 20x magnification higher-power image of the thickened subepithelial collagen table, showing diagnostic features of entrapped cellular elements such as inflammatory cells and blood vessels.

Figure 2.

Figure 2

Open in a new tab

(a) 10x magnification of histopathology of the polypoid gastric body lesion showing poorly differentiated adenocarcinoma with surface ulceration. (b) High-power magnification of the gastric polypoid lesion showing high-grade dysplasia. (c) EBV-infected carcinoma cells (black stain present) juxtaposed with normal gastric glandular mucosa (black stain absent), using EBV-related encoded RNA in situ hybridization assay (EBER ish).

2.2. Sample Preparation

Peripheral blood was drawn from the patient following the diagnosis of gastric adenocarcinoma and from age- and gender-matched control. Peripheral blood mononuclear cells (PBMCs) were isolated from blood by using density gradient lymphocyte separation media. Human Subject Committee of the Institution Review Board of the University of California, Irvine, approved the protocol. Signed written consent was obtained.

2.3. Antibodies and Reagents

The following anti-human monoclonal antibodies and isotype controls were purchased from BD Biosciences (San Jose, California): CD4 PerCP, CD8 PerCP, CD45RA APC, CCR7 FITC, CD183 PE, CD25 FITC, CD127 AL647, FoxP3 PE, CD278 (ICOS) AL647, CD183 BV421, CXCR5 AL488, PD1 APC, CD8 BV421, CD45RA BV510, CD19 PerCP, CD38 FITC, and CD24 FITC.

2.4. Flow Cytometry

Approximately 1 million PBMCs were used per combination for antibody staining. 20 μl of antibody was added to PBMCs for 30 min. PBMCs were washed and fixed by 2% paraformaldehyde (PFA).

For regulatory cells, the following surface staining cells were fixed and permeablized by using a Foxp3 staining buffer set (BD Bioscience, San Jose, California) as per the manufacturer's protocol. Intracellular staining with anti-Foxp3PE monoclonal antibody, and appropriate isotype control (Mouse IgG1k-PE), was used for nonspecific staining.

All flourescence minus one controls and isotype controls were stained and fixed by 2% PFA for flow cytometry. Cells were acquired by using the BD FACS Celesta (Becton-Dickenson, San Jose, CA) equipped with a BVR laser. Forward and side scatters and singlets were used to gate and exclude cellular debris. Thirty thousand cells were acquired and analyzed using FLOWJO software (Ashland, OR).

The following surface makers identified various lymphocyte subsets:

  •   Subsets of CD4 T cells and CD8+ T cells: naïve (TN)-CD4+/CD8+CD45RA+CCR7+, central memory (TCM)-CD4+/CD8+CD45RA-CCR7+, effector memory (TEM)-CD4+/CD8+CD45RA-CCR7-, CD45RA+effector memory, and terminally differentiated effector memory (TEMRA)-CD4+/CD8+CD45RA+CCR7-

  •   Subsets of T follicular helper cells: cTFH-CD4+CXCR5+CD45RA-, TFH1-CD4+CXCR5+CD45RA-CCR6-CXCR3+, TFH2-CD4+CXCR5+CD45RA-CCR6-CXCR3, TFH17-CD4+CXCR5+CD45RA-CCR6+CXCR3, and TFH1+TFH17-CD4+CXCR5+CD45RA-CCR6+CXCR3+

  •   Regulatory lymphocytes: CD4Treg–CD4+CD25+CD127- Foxp3+; CD8 Treg-CD8+CD183+CCR7+CD45RA-FoxP3+; TFR-CD4+CCR5+CD45RA-CD25highFoxP3+; and Breg-CD19+CD24+CD38+

3. Results

3.1. Subsets of CD4 and CD8 T Cells

Naive T cells (TN) upon activation with an antigen undergo clonal expansion and differentiation to effector cells, and at the end of immune response, they are retained as memory T cells. Based on their homing properties, expression of adhesion molecules, and chemokine receptors, memory T cells are classified into central memory (TCM) and effector memory (TEM) CD4+ and CD8+ T cells [15, 16]. A small population of TEM cells reacquire CD45RA and are termed as terminally differentiated effector memory T cells (TEMRA). These subsets differ with regard to proliferative response, cytokine production, effector properties, and sensitivity to apoptosis [15]. Therefore, we examined these subsets in our patient. CD4 TN were decreased, and CD4 TCM were increased (Figure 3(a)). CD8 TN and TCM increased, whereas TEM was decreased (Figure 3(b)).

Figure 3.

Figure 3

Open in a new tab

(a) CD4 subsets: CD4+ subsets are characterized by different makers; naïve (TN; CCR7+CD45RA+) central memory: TCM (CCR7+CD45RA-), effector memory: TEM (CCR7-CD45RA-), T effector memory RA: TEMRA (CCR7-CD45RA+). (b) CD8 subset: CD8+ gated cells. In PBMCs, CD88+ T cells were gated and gated CD8+ cells subsets are characterized by different makers: TN (CCR7+ CD45RA+), TCM (CCR7+CD45RA-), TEM (CCR7-CD45RA-), and TEMRA (CCR7-CD45RA+). Abnormal values are circled in red.

3.2. Subsets of Follicular Helper T Cells

Circulating TFH cells (cTFH) play an important role in germinal center formation, immunoglobulin isotype switching, and differentiation of B cells to immunoglobulin-secreting cells [17, 18]. The signature cytokine they produce is IL-21. However, based on additional cytokines produced, cTFH has been further classified into TFH1, TFH2, and TFH17 [19]. Therefore, we examined all subsets of cTFH. cTFH, TFH1, and TFH2, whereas TFH17 was reduced as compared to control (Figure 4).

Figure 4.

Figure 4

Open in a new tab

TFH cells: in PBMCs, CD4+ gated cells and various TFH subsets were characterized by different makers: cTFH-CXCR5+CD45RA- and TFH subsets TFH1 (CXCR3+CCR6-), THF1+THF17 (CXCR3+CCR6+), TFH2 (CXCR3-CCR6), and TFH17 (CXCR3-CCR6+). Abnormal values are circled in red. (a) CD4+T-cell subsets. (b) CD8+T-cell subsets.

3.3. Regulatory Lymphocytes

There are 4 members of the “regulatory club” [20–24]. CD4 Treg plays an important role in immune tolerance and cancer [22]. In addition, T follicular regulatory cells (TFR) regulate the function of cTFH cells [20, 21]. In addition, CD8 Treg and Breg have also been shown to play a role in peripheral tolerance in cancer [23, 24]. Therefore, we examined all 4 regulatory lymphocytes. TFR cells and CD4 Treg were increased, whereas B reg and CD8 Treg were comparable to control (Figure 5).

Figure 5.

Figure 5

Open in a new tab

Regulatory lymphocytes: CD4Treg gated CD4+ cells for CD25+CD127- and then analyzed as CD4+CD25+CD127-Foxp3+ cells. Abnormal values are circled in red. CD8 Treg: gated CCR7+CD25highCD45RA- CD8 T cells expressing CD183 (CXCR3) and FoxP3. TFR cells were characterized as TFR-CD4+CCR5+CD45RA-CD25highFoxP3+ and Breg as CD19+CD24+CD38+.

4. Discussion

SIgMD is a rare primary immunodeficiency disease characterized by low serum IgM and normal IgG and IgA; B cells with surface membrane IgM are normal [6]. We present the 1st SIgMD patient who developed collagenous gastritis that transitioned to EBV + gastric adenocarcinoma.

Collagenous infiltrative disorders of the gastrointestinal tract are characterized by subepithelial deposition of collagen bands with mononuclear cell infiltration in the mucosa [25]. In 1989, Colleti and Trainer [26] reported the first case of collageneous gastritis in a 15-year-old girl who presented with recurrent abdominal pain and bleeding. Collagenous gastritis is extremely rare; since 1989, less than 70 cases of collagenous gastritis have been reported. A few cases of collagenous gastroenteritis have been reported in primary immunodeficiency diseases [27–31]; however, isolated collagenous gastritis has been reported only in one case of hypogammaglobulinemia [32] and in one case of selective IgA deficiency [33]. Ours is the first case of collagenous gastritis in SIgMD. The pathogenesis of collagenous disorders of the gastrointestinal tract remains unclear. A role of the immune system has been proposed based on collagenous gastroenteritis in autoimmune diseases including systemic lupus erythematosus, Sjogren's syndrome, celiac disease, and ulcerative colitis [34–39]. Freeman reported celiac disease in more than 20% of patients with collagenous colitis, a rate that exceeds the reported detection rates of celiac disease in other clinical settings [40].

In a long-term follow-up of patients with collagenous gastritis ranging from 2–16 years, no case of gastric cancer has been observed [41, 42]. However, colon cancer has been rarely recorded in collagenous colitis [43]. Also intriguing was the coincidental later development of lymphomas in 2 patients with collagenous colitis in the absence of celiac disease [40]. Previous reports have recorded Hodgkin and non-Hodgkin lymphomas, including a mycosis fungoides-type T-cell lymphoma in collagenous colitis [44–46]. Additional studies will be needed to determine if there is an increased risk for these lymphoproliferative malignancies in collagenous colitis.

Gastric cancer is the fourth most common cancer and the second leading cause of death worldwide [47]. Gastric cancer is the most common cause of death among CVID patients [48]. Epstein–Barr virus (EBV) is detected in 10% of gastric adenocarcinoma patients [49–54]. Hepatitis B virus (HBV) and Helicobacter pylori (H. Pylori) have also been implicated in gastric cancer [49]. Kamimura et al. [42] reviewed all 60 patients of collagenous gastritis reported in the world literature until 2015 with a follow-up ranging from 2–14 years. They reported 6 adults and 4 children with collagenous gastritis that were positive for H. pylori. None of the patients with collagenous gastritis have ever progressed to gastric cancer. Our patient was negative for H. pylori infection. In addition to H. pylori and EBV, other predisposing factors for gastric cancer include atropic gastritis and pernicious anemia. Gastric malignancy has not been described in SIgMD. Gastric adenocarcinoma has been reported in patients with other primary immunodeficiencies; however, none were reported to be EBV+ [48, 55–62]. Our patient was diagnosed with collagenous gastritis eight years prior to the development of EBV + adenocarcinoma. Furthermore, at the time of diagnosis, no EBV viremia was present.

In order to understand a role of immune responses in gastric cancer in our patient, we examined various subsets of CD4+ and CD8+ T cells and regulatory lymphocytes. Zhang et al [63] reported increased TFH1 cells that promote inflammation, suppress Breg, and correlate with worse clinical outcome in gastric cancer. Our patient, who had mild course of the disease, also had increased TFH1 cells, but normal Breg cells, suggesting Breg may play a role in clinical outcome of gastric adenocarcinoma. Murakami et al. [64] reported increased regulatory B cells in gastric cancer and suggested that Breg may play a role in immune evasion in gastric cancer. In contrast, Hu et al. [65] reported that IL-10-expressing B cells (Breg) were highly enriched in tumor-infiltrating B cells and were present at reduced frequencies in circulating B cells. Furthermore, they demonstrated that these Breg suppressed cytokine production by CD4+ (IFN-γ, TNFα, and IL-17) and CD8+ T cells (IFN-γ and TNF-α). Wang et al. [66] also observed that Breg suppressed TH1 CD4+ T cells (IFN-γ) and induced CD4+ Treg and suggested that increased CD4 Treg might contribute to immune escape in gastric cancer. However, in our patient, CD4 Treg was increased and Breg was comparable to control, yet he had a favorable outcome. In SIgMD, Breg and CD8 Treg are increased, whereas CD4 Treg is comparable to control [67]. Therefore, changes in regulatory lymphocytes in our patient are distinct from those in SIgMD and may suggest their role in transition of collagenous gastritis to gastric adenocarcinoma.

5. Conclusions

In summary, we described the first case of SIgMD with isolated collagenous gastritis that transitioned to gastric adenocarcinoma. Furthermore, this is the 1st case of EBV + gastric adenocarcinoma in any primary immunodeficiency. The role of immunological alterations in transition of collagenous gastric to EBV + gastric adenocarcinoma is unclear; however, regulatory lymphocytes may play a role in clinical outcome.

Acknowledgments

This work was supported by unrestricted funds of the Division of Basic and Clinical Immunology, University of California, Irvine.

Data Availability

Readers can access the data supporting the conclusions of this study by requesting from the corresponding author.

Conflicts of Interest

All authors declare no conflicts of interest.

Authors' Contributions

TN collected clinical data and wrote the manuscript. HS performed flow cytometry. SG conceived the idea, supervised HS, analyzed the data, and wrote the manuscript.

References

  • 1.Hobbs J. R., Milner R. D., Watt P. J. Gamma-M deficiency predisposing to meningococcal septicaemia. BMJ. 1967;4(5579):583–586. doi: 10.1136/bmj.4.5579.583. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 2.Bousfiha A., Jeddane L., Picard C., et al. The 2017 IUIS phenotypic classification for primary immunodeficiencies. Journal of Clinical Immunology. 2018;38(1):129–143. doi: 10.1007/s10875-017-0465-8. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 3.Gupta S., Gupta A. Defining primary selective IgM deficiency. Journal of Clinical Immunology. 2019;39(4):350–352. doi: 10.1007/s10875-019-00641-4. [DOI] [PubMed] [Google Scholar]
  • 4.Louis A. G., Gupta S. Primary selective IgM deficiency: an ignored immunodeficiency. Clinical Reviews in Allergy & Immunology. 2014;46(2):104–111. doi: 10.1007/s12016-013-8375-x. [DOI] [PubMed] [Google Scholar]
  • 5.Lucuab-Fegurgur D. L., Gupta S. Comprehensive clinical and immunological features of 62 adult patients with selective primary IgM deficiency. American Journal of Clinical and Experimental Immunology. 2019;8:55–67. [PMC free article] [PubMed] [Google Scholar]
  • 6.Gupta S., Gupta A. Selective IgM deficiency-an underestimated primary immunodeficiency. Frontiers in Immunology. 2017;8:1056. doi: 10.3389/fimmu.2017.01056. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 7.Gupta S., Agrawal S. IgAλ monoclonal gammopathy of undetermined significance (MGUS) associated with primary selective IgM deficiency. American Journal of Clinical and Experimental Immunology. 2019;8:37–46. [PMC free article] [PubMed] [Google Scholar]
  • 8.Nielsen O. H., Riis L. B., Danese S., Bojesen R. D., Soendergaard C. Proximal collagenous gastroenteritides: clinical management. A systematic review. Annals of Medicine. 2014;46(5):311–317. doi: 10.3109/07853890.2014.899102. [DOI] [PubMed] [Google Scholar]
  • 9.Rustagi T., Rai M., Scholes J. V. Collagenous gastroduodenitis. Journal of Clinical Gastroenterology. 2011;45(9):794–799. doi: 10.1097/mcg.0b013e31820c6018. [DOI] [PubMed] [Google Scholar]
  • 10.Gopal P., McKenna B. J. The collagenous gastroenteritides: similarities and differences. Archives of Pathology & Laboratory Medicine. 2010;134(10):1485–1489. doi: 10.5858/2010-0295-cr.1. [DOI] [PubMed] [Google Scholar]
  • 11.Brain O., Rajaguru C., Warren B., Booth J., Travis S. Collagenous gastritis: reports and systematic review. European Journal of Gastroenterology & Hepatology. 2009;21(12):1419–1424. doi: 10.1097/meg.0b013e32832770fa. [DOI] [PubMed] [Google Scholar]
  • 12.Freeman H.-J. Complications of collagenous colitis. World Journal of Gastroenterology. 2008;14(11):1643–1645. doi: 10.3748/wjg.14.1643. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 13.Ma C., Park J. Y., Montgomery E. A., et al. A comparative clinicopathologic study of collagenous gastritis in children and adults. American Journal of Surgical Pathology. 2015;39(6):802–812. doi: 10.1097/PAS.0000000000000441. [DOI] [PubMed] [Google Scholar]
  • 14.Kamimura K., Kobayashi M., Sato Y., Aoyagi Y., Terai S. Collagenous gastritis: review. World Journal of Gastrointestinal Endoscopy. 2015;7(3):265–273. doi: 10.4253/wjge.v7.i3.265. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 15.Gupta S. Molecular mechanisms of apoptosis in the cells of the immune system in human aging. Immunological Reviews. 2005;205(1):114–129. doi: 10.1111/j.0105-2896.2005.00261.x. [DOI] [PubMed] [Google Scholar]
  • 16.Sallusto F., Lenig D., Förster R., Lipp M., Lanzavecchia A. Two subsets of memory T lymphocytes with distinct homing potentials and effector functions. Nature. 1999;401(6754):708–712. doi: 10.1038/44385. [DOI] [PubMed] [Google Scholar]
  • 17.Uneo H. Human circulating T follicular helper cell subsets in health and disease. Journal of Clinical Immunology. 2016;36(suppl 1):34–39. doi: 10.1007/s10875-016-0268-3. [DOI] [PubMed] [Google Scholar]
  • 18.Crotty S. T follicular helper cell biology: a decade of discovery and diseases. Immunity. 2019;50(5):1132–1148. doi: 10.1016/j.immuni.2019.04.011. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 19.Morita R., Schmitt N., Bentebibel S.-E., et al. Human blood CXCR5+CD4+ T cells are counterparts of T follicular cells and contain specific subsets that differentially support antibody secretion. Immunity. 2011;34(1):108–121. doi: 10.1016/j.immuni.2010.12.012. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 20.Zhu Y., Zou L., Liu Y.-C. T follicular helper cells, T follicular regulatory cells and autoimmunity. International Immunology. 2016;28(4):173–179. doi: 10.1093/intimm/dxv079. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 21.Wollenberg I., Agua-Doce A., Hernández A., et al. Regulation of the germinal center reaction by Foxp3+ follicular regulatory T cells. The Journal of Immunology. 2011;187(9):4553–4560. doi: 10.4049/jimmunol.1101328. [DOI] [PubMed] [Google Scholar]
  • 22.Sakaguchi S., Miyara M., Costantino C. M., Hafler D. A. FOXP3+ regulatory T cells in the human immune system. Nature Reviews Immunology. 2010;10(7):490–500. doi: 10.1038/nri2785. [DOI] [PubMed] [Google Scholar]
  • 23.Flippe L., Bézie S., Anegon I., Guillonneau C. Future prospects for CD8+ regulatory T cells in immune tolerance. Immunological Reviews. 2019;291:209–224. doi: 10.1111/imr.12812. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 24.Mauri C., Blair P. A. Regulatory B cells in autoimmunity: developments and controversies. Nature Reviews Rheumatology. 2010;6(11):636–643. doi: 10.1038/nrrheum.2010.140. [DOI] [PubMed] [Google Scholar]
  • 25.Lagorce-Pages C., Fabiani B., Bouvier R., Scoazec J.-Y., Durand L., Flejou J.-F. Collagenous gastritis. The American Journal of Surgical Pathology. 2001;25(9):1174–1179. doi: 10.1097/00000478-200109000-00008. [DOI] [PubMed] [Google Scholar]
  • 26.Colletti R. B., Trainer T. D. Collagenous gastritis. Gastroenterology. 1989;97(6):1552–1555. doi: 10.1016/0016-5085(89)90403-4. [DOI] [PubMed] [Google Scholar]
  • 27.Pariente E. A., Chaumette M. T., Maître F., Delchier J. C., Soulé J. C., Bader J. P. Collagenous colitis, IgA deficiency, Basedow’s disease and atrophic gastritis. Gastroentérologie Clinique et Biologique. 1985;9:738–741. [PubMed] [Google Scholar]
  • 28.Daniels J. A., Lederman H. M., Maitra A., Montgomery E. A. Gastrointestinal tract pathology in patients with common variable immunodeficiency (CVID) American Journal of Surgical Pathology. 2007;31(12):1800–1812. doi: 10.1097/PAS.0b013e3180cab60c. [DOI] [PubMed] [Google Scholar]
  • 29.Byrne M. F., Royston D., Patchett S. E. Association of common variable immunodeficiency with atypical collagenous colitis. European Journal of Gastroenterology & Hepatology. 2003;15(9):1051–1053. doi: 10.1097/00042737-200309000-00019. [DOI] [PubMed] [Google Scholar]
  • 30.Yong P. F., Li H., Chung-Faye G., Ibrahim M. A. Collagenous colitis in a patient with common variable immunodeficiency. Journal of Investigational Allergology & Clinical Immunology. 2008;18:482–483. [PubMed] [Google Scholar]
  • 31.Navarro-Llavat M., Domènech E., Masnou H., et al. Collagenous duodeno-ileo-colitis with transient IgG deficiency preceded by Yersinia enterocolitica intestinal infection: case report and review of literature. Gastroenterología Y Hepatología. 2007;30(4):219–221. doi: 10.1157/13100588. [DOI] [PubMed] [Google Scholar]
  • 32.Mandaliya R., Burkart A. L., DiMarino A. J., Rattan S., Cohen S. Association between common variable immunodeficiency and collagenous infiltrative disorders of the gastrointestinal tract: a series of four patients. Indian Journal of Gastroenterology. 2016;35(2):133–138. doi: 10.1007/s12664-016-0633-4. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 33.Anwar M. S., Aamar A., Marhaba A., Sidhu J. S. Collagenous Gastritis in a young female with IgA deficiency. Gastroenterology Research. 2017;10(2):126–127. doi: 10.14740/gr748w. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 34.O’Mahony S., Nawroz I. M., Ferguson A. Coeliac disease and collagenous colitis. Postgraduate Medical Journal. 1990;66:238–241. doi: 10.1136/pgmj.66.773.238. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 35.Stancu M., De Petris G., Palumbo T. P., Lev R. Collagenous gastritis associated with lymphocytic gastritis and celiac disease. Archives of Pathology & Laboratory Medicine. 2001;125(12):1579–1584. doi: 10.5858/2001-125-1579-cgawlg. [DOI] [PubMed] [Google Scholar]
  • 36.Perisic V. N., Kokai G., Pavlovic M. Coeliac disease and collagenous colitis. The Italian Journal of Gastroenterology. 1992;24:418–420. [PubMed] [Google Scholar]
  • 37.Gillett H. R., Freeman H. J. Prevalence of celiac disease in collagenous and lymphocytic colitis. Canadian Journal of Gastroenterology. 2000;14(11):919–921. doi: 10.1155/2000/847807. [DOI] [PubMed] [Google Scholar]
  • 38.Al-Kandari A., Al-Alardati H., Sayadi H., Al-Judaibi B., Mawardi M. An unusual case of collagenous gastritis in a middle-aged woman with systemic lupus erythromatosis: a case report. Journal of Medical Case Reports. 2014;8:278. doi: 10.1186/1752-1947-8-278. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 39.Vesoulis Z., Lozanski G., Ravichandran P., Esber E. Collagenous gastritis: a case report, morphologic evaluation, and review. Modern Pathology. 2000;13(5):591–596. doi: 10.1038/modpathol.3880101. [DOI] [PubMed] [Google Scholar]
  • 40.Freeman H. J. Collagenous colitis as the presenting feature of biopsy-defined celiac disease. Journal of Clinical Gastroenterology. 2004;38(8):664–668. doi: 10.1097/01.mcg.0000135363.12794.2b. [DOI] [PubMed] [Google Scholar]
  • 41.Winslow J. L., Trainer T. D., Colletti R. B. Collagenous gastritis. American Journal of Clinical Pathology. 2001;116(5):753–758. doi: 10.1309/3WM2-THU3-3Q2A-DP47. [DOI] [PubMed] [Google Scholar]
  • 42.Chan J. L., Tersmette A. C., Offerhaus J. G. A., Gruber S. B., Bayless T. M., Giardiello F. M. Cancer risk in collagenous colitis. Inflammatory Bowel Diseases. 1999;5(1):40–43. doi: 10.1097/00054725-199902000-00006. [DOI] [PubMed] [Google Scholar]
  • 43.Gardiner G. W., Goldberg R., Currie D., Murray D. Colonic carcinoma associated with an abnormal collagen table: collagenous colitis. Cancer. 1984;54(12):2973–2977. doi: 10.1002/1097-0142(19841215)54:12&#x0003c;2973::aid-cncr2820541227&#x0003e;3.0.co;2-f. [DOI] [PubMed] [Google Scholar]
  • 44.van der Werf S. D., van Berge Henegouwen G. P., Bronkhorst F. B., Werre J. M. Chemotherapy responsive collagenous colitis in a patient with Hodgkin’s disease: a possible paraneoplastic phenomenon. The Netherlands Journal of Medicine. 1987;31:228–233. [PubMed] [Google Scholar]
  • 45.Edwards D. B. Collagenous colitis and histiocytic lymphoma. Annals of Internal Medicine. 1989;111(3):260–261. doi: 10.7326/0003-4819-111-3-260. [DOI] [PubMed] [Google Scholar]
  • 46.Ouyaya F., Michenet P., Gargot D., et al. Lymphocytic colitis, followed by collagenous colitis, associated with mycosis fungoides-type T-cell lymphoma. Gastroentérologie Clinique et Biologique. 1993;17:976–977. [PubMed] [Google Scholar]
  • 47.Correa P., Piazuelo M. B., Camargo M. C. The future of gastric cancer prevention. Gastric Cancer. 2004;7(1):9–16. doi: 10.1007/s10120-003-0265-0. [DOI] [PubMed] [Google Scholar]
  • 48.Pulvirenti F., Pecoraro A., Cinetto F., et al. Gastric cancer is the leading cause of death in Italian adult patients with common variable immunodeficiency. Frontiers in Immunology. 2018;9:2546. doi: 10.3389/fimmu.2018.02546. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 49.Niedźwiedzka-Rystwej P., Grywalska E., Hrynkiewicz R., Wołącewicz M., Becht R., Roliński J. The double-edged sword role of viruses in gastric cancer. Cancers (Basel) 2020;12(6):1680. doi: 10.3390/cancers12061680. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 50.Nishikawa J., Yoshiyama H., Iizasa H., et al. Epstein-barr virus in gastric carcinoma. Cancers. 2014;6(4):2259–2274. doi: 10.3390/cancers6042259. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 51.Takada K. Epstein-Barr virus and gastric carcinoma. Molecular Pathology. 2000;53(5):255–261. doi: 10.1136/mp.53.5.255. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 52.Shibata D., Weiss L. M. Epstein-Barr virus-associated gastric adenocarcinoma. The American Journal of Pathology. 1992;140(4):769–774. [PMC free article] [PubMed] [Google Scholar]
  • 53.Ryan J. L., Morgan D. R., Dominguez R. L., et al. High levels of epstein-barr virus DNA in latently infected gastric adenocarcinoma. Laboratory Investigation. 2009;89(1):80–90. doi: 10.1038/labinvest.2008.103. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 54.van Beek J., zur Hausen A., Klein Kranenbarg E., et al. EBV-positive gastric adenocarcinomas: a distinct clinicopathologic entity with a low frequency of lymph node involvement. Journal of Clinical Oncology. 2004;22(4):664–670. doi: 10.1200/jco.2004.08.061. [DOI] [PubMed] [Google Scholar]
  • 55.Gathmann B., Mahlaoui N., Gérard L., et al. Clinical picture and treatment of 2212 patients with common variable immunodeficiency. Journal of Allergy and Clinical Immunology. 2014;134(1):116–126. doi: 10.1016/j.jaci.2013.12.1077. [DOI] [PubMed] [Google Scholar]
  • 56.Kinlen L. J., Webster A. D. B., Bird A. G., et al. Prospective study of cancer in patients with hypogammaglobulinaemia. The Lancet. 1985;325(8423):263–266. doi: 10.1016/S0140-6736(85)91037-2. [DOI] [PubMed] [Google Scholar]
  • 57.Gullo I., Costa C., Silva S. L., et al. The dysfunctional immune system in common variable immunodeficiency increases the susceptibility to gastric cancer. Cells. 2020;9(6):1498. doi: 10.3390/cells9061498. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 58.Bratanič N., Kovač J., Pohar K., et al. Multifocal gastric adenocarcinoma in a patient with LRBA deficiency. Orphanet Journal of Rare Diseases. 2017;12(1):131. doi: 10.1186/s13023-017-0682-5. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 59.Dhalla F., da Silva S. P., Lucas M., Travis S., Chapel H. Review of gastric cancer risk factors in patients with common variable immunodeficiency disorders, resulting in a proposal for a surveillance programme. Clinical & Experimental Immunology. 2011;165(1):1–7. doi: 10.1111/j.1365-2249.2011.04384.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 60.Agarwal S., Mayer L. Diagnosis and treatment of gastrointestinal disorders in patients with primary immunodeficiency. Clinical Gastroenterology and Hepatology. 2013;11(9):1050–1063. doi: 10.1016/j.cgh.2013.02.024. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 61.De Petris G., Dhungel B. M., Chen L., Chang Y.-H. H. Gastric adenocarcinoma in common variable immunodeficiency. International Journal of Surgical Pathology. 2014;22(7):600–606. doi: 10.1177/1066896914532540. [DOI] [PubMed] [Google Scholar]
  • 62.Leone P., Vacca A., Dammacco F., Racanelli V. Common variable immunodeficiency and gastric malignancies. International Journal of Molecular Sciences. 2018;19(2):451. doi: 10.3390/ijms19020451. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 63.Zhang H., Yue R., Zhao P., et al. Proinflammatory follicular helper T cells promote immunoglobulin G secretion, suppress regulatory B cell development, and correlate with worse clinical outcomes in gastric cancer. Tumor Biology. 2017;39(6) doi: 10.1177/1010428317705747.101042831770574 [DOI] [PubMed] [Google Scholar]
  • 64.Murakami Y., Saito H., Shimizu S., et al. Increased regulatory B cells are involved in immune evasion in patients with gastric cancer. Scientific Reports. 2019;9(1):p. 13083. doi: 10.1038/s41598-019-49581-4. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 65.Hu H.-T., Ai X., Lu M., Song Z., Li H. Characterization of intratumoral and circulating IL-10-producing B cells in gastric cancer. Experimental Cell Research. 2019;384(2) doi: 10.1016/j.yexcr.2019.111652.111652 [DOI] [PubMed] [Google Scholar]
  • 66.Wang W., Yuan X., Chen H., et al. CD19+CD24hiCD38hiBregs involved in downregulate helper T cells and upregulate regulatory T cells in gastric cancer. Oncotarget. 2015;6(32):33486–33499. doi: 10.18632/oncotarget.5588. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 67.Louis A. G., Agrawal S., Gupta S. Analysis of subsets of B cells, Breg, CD4Treg and CD8Treg cells in adult patients with primary selective IgM deficiency. American Journal of Clinical and Experimental Immunology. 2016;5:21–32. [PMC free article] [PubMed] [Google Scholar]

Associated Data

This section collects any data citations, data availability statements, or supplementary materials included in this article.

Data Availability Statement

Readers can access the data supporting the conclusions of this study by requesting from the corresponding author.

Articles from Case Reports in Immunology are provided here courtesy of Wiley

RESOURCES